Main Uses and Benefits of Ebastel D

The combination of ebastine and pseudoephedrine is generally used for managing the symptomatic treatment of allergic rhinitis, particularly when accompanied by nasal congestion. This is a condition characterized by periods of heightened symptoms such as sneezing, runny nose, and ocular irritation. It is applied across domains where additional symptomatic support is needed for the symptom cluster of allergic discomfort and physical obstruction.

The medication is commonly used across conditions presenting with acute episodes of seasonal (episodic) and perennial (recurrent) allergic rhinitis. These are situations where symptoms related to physical discomfort intensify and supportive relief is needed. The combination approach may contribute to easing discomfort and assists with managing symptom clusters that may become intense or disruptive.

“The primary benefit provides support that helps ease the overall symptom burden, contributing to easing discomfort during symptomatic periods.”

This therapeutic focus supports a sense of stability when symptoms are more noticeable, and may assist patients in coping more steadily with symptom fluctuations arising from exposure to allergens like pollen or dust mites.

---

Quick Fact: Relief for Nasal Congestion

Property	Description
Primary Use Focus	Symptomatic relief of allergic rhinitis with co-occurring nasal congestion
Symptom Clusters	Nasal stuffiness, runny nose, sneezing, and itchy/watery eyes
Condition Types	Seasonal (episodic) and perennial (recurrent) allergies
Patient Benefit	Supports assistance with maintaining functional stability and eases overall symptom burden

Eligibility Map: Who can and cannot use Ebastel D — Official Regulatory Information

---

Eligibility Scope

Classification	Population/Condition
Populations for whom use is allowed	Adults and Adolescents (typically ge 12 years).
Populations for whom use is not recommended	Children below the minimum approved age; Breastfeeding women.
Populations for whom use is contraindicated	Patients with severe or uncontrolled hypertension; severe coronary artery disease; hyperthyroidism; closed-angle glaucoma; diabetes mellitus; phaeochromocytoma; hypersensitivity to components; current or recent use of MAO Inhibitors; Pregnant women.

---

Condition-Specific Eligibility Rules

Category	Restriction
Organ Impairment	Restricted use in severe hepatic impairment (dose limit applies) and severe renal impairment; caution advised in mild-to-moderate cases.
Other Comorbidities	Prostatic hypertrophy (risk of urinary retention); conditions predisposing to QTc interval prolongation or known cardiac arrhythmias.

---

Eligibility Classifications (High-Level)

Classification	Status
Eligibility severity classification	Contraindicated, Not Recommended, Use with Caution.
Regulatory basis	Summary of Product Characteristics (SmPC) and equivalent National Regulatory Authority documents.

---

Official eligibility statements:

• The medicine is contraindicated in patients with severe hypertension, severe coronary artery disease, and diabetes mellitus.
• Use is generally not recommended in children under 12 years and in women who are pregnant or breastfeeding.
• The drug is contraindicated for use with or within two weeks of stopping Monoamine Oxidase Inhibitors (MAOIs).

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use Ebastel D by establishing absolute prohibitions (contraindications) based on the cardiovascular and metabolic risks associated with the pseudoephedrine component. Further use is restricted based on age limits, insufficient data in young children, and physiological states such as pregnancy and lactation.

Interactions with other medicines and products

Contraindicated and Restricted Combinations

The Pseudoephedrine component of this combination product is contraindicated with the use of Monoamine Oxidase Inhibitors (MAOIs). This restriction also applies for a period of fourteen days after stopping MAOI therapy. Co-administration of the antihistamine component, Ebastine, is generally not recommended with strong inhibitors of the cytochrome P450 3A4 (CYP3A4) enzyme.

Pharmacokinetic and Exposure Effects

Strong CYP3A4 inhibitors, such as the antifungals Ketoconazole and Itraconazole or the macrolide antibiotics Erythromycin and Clarithromycin, are documented to cause an increase in the plasma concentrations of Ebastine and its active metabolite, Carebastine. Conversely, the co-administration of the potent CYP3A4 inducer Rifampicin results in reduced plasma levels of Ebastine, leading to a diminished antihistamine effect.

Pharmacodynamic and Other Interactions

Due to the Pseudoephedrine component, co-administration with other sympathomimetic agents may result in additive effects, and use with Digitalis may increase ectopic pacemaker activity. The rate of Pseudoephedrine clearance is dependent on urinary pH.

Food and Population Considerations

Food intake is documented to increase the plasma levels of the active metabolite, Carebastine, by 1.5 - to 2.0 -fold, though this is not noted as affecting clinical efficacy. For patients with severe hepatic insufficiency, a specific daily dose restriction (e.g., 10 mg) of Ebastine is required.

Ebastel D combines two distinct pharmacodynamic agents: Ebastine and Pseudoephedrine.

Ebastine acts as a long-acting, selective inverse agonist at peripheral Histamine H1 receptors ( HRH1). This interaction stabilizes the HRH1 in its inactive state, thereby preventing the constitutive or histamine-mediated activation of the Gq/ G11 protein signaling cascade. Downstream, this modulates the phospholipase C pathway, reducing inositol triphosphate ( IP3) and diacylglycerol ( DAG) production, which in turn attenuates the release of intracellular Ca^2+. This suppression of HRH1 signaling decreases the activity of transcription factors like NF-kappa B and AP-1, leading to a modulation of inflammatory mediator expression in target tissues.

Pseudoephedrine functions as a sympathomimetic agent, acting through dual mechanisms. Primarily, it is an agonist at postsynaptic alpha1-adrenergic receptors, particularly those located on the smooth muscle of blood vessels in the nasal mucosa. This direct receptor activation triggers a Gq-protein cascade, promoting vasoconstriction. Secondarily, pseudoephedrine acts as an indirectly acting agent by binding to the norepinephrine transporter, promoting the release of endogenous norepinephrine into the synaptic cleft, further stimulating alpha1 and beta-adrenergic receptors. The system-level physiological consequence of alpha1-adrenergic vasoconstriction is reduced blood flow to the nasal vasculature.

The administration of the Ebastel D fixed-dose combination (Ebastine / Pseudoephedrine) is officially confined to the oral route. The standard regimen for adults and adolescents (aged 12 and above) is one FDC unit (10 mg Ebastine / 120 mg Pseudoephedrine) taken once daily. The maximum prescribed dosing schedule permits the intake of one unit every 12 hours, limiting the total daily intake to two units.

---

This medication is designated for short-term usage for symptomatic relief, with official guidelines often recommending a duration of use not exceeding seven days. Procedurally, the FDC unit must be swallowed whole; the unit must not be crushed, broken, or chewed to preserve the sustained-release mechanism of the decongestant component.

---

Administration is generally independent of food intake, though regulatory documents often suggest morning use. A specific population-based instruction requires that the daily dose must not exceed one FDC unit for patients with severe hepatic impairment, thus prohibiting the maximum twice-daily regimen. In the event of a missed dose, the procedure is to take the dose when remembered unless the next scheduled dose is imminent, in which case the missed unit should be skipped to prevent doubling.

Research Evidence / Overview of Studies for Ebastel D

The research base for the Ebastel D combination medicine is based on research into how the two active components, Ebastine and Pseudoephedrine, were evaluated in research settings associated with allergic rhinitis. The available evidence, largely gathered through official clinical trials, describes patterns observed so far about the medicine in specific research settings.

---

Evidence for Symptom Management in Allergic Rhinitis

Research exploring the fixed-dose combination (Ebastine and Pseudoephedrine) was mainly conducted using short-term, randomized controlled trials (RCTs). These studies were conducted during periods of increased symptom activity, primarily focusing on conditions characterized by fluctuating or episodic manifestations of allergic rhinitis, especially when accompanied by nasal congestion. The research examined patient-reported outcomes describing perceived discomfort and outcomes related to physical discomfort. Studies monitored patterns observed during the short-term period, and research describes how symptoms evolved in the observed populations.

---

The Role of Monotherapy Component Research

Research into the Ebastine monotherapy component alone contributes to the overall evidence base that regulatory bodies evaluate. Ebastine was evaluated in numerous randomized controlled trials and comprehensive systematic reviews across allergic rhinitis and conditions such as chronic urticaria. The findings from these monotherapy studies describe group patterns but not individual outcomes related to the combination product, which includes the decongestant pseudoephedrine.

---

Research Gaps and Uncertainties

While the existing research contributes to understanding short-term symptom patterns, the overall evidence profile highlights several areas where knowledge is still developing.

• Long-term effects are not fully established: The research primarily focuses on acute use, meaning there is limited information to characterize the outcomes of long-term or continuous treatment.
• Subgroup findings are uncertain: Data for specific subgroups, including children under 12, older adults, and those with underlying health conditions, remain insufficient.

Key Studies & References Summary Public Assessment Report Ebastine Sandoz (ebastine) SE/H/1209/01-02/DC

Common questions about Ebastel D (FAQ)

---

Q: What is the main purpose of taking Ebastel D?

Official product information describes the main purpose of this combination medicine as the symptomatic treatment of conditions such as allergic rhinitis. This includes addressing the symptoms of nasal congestion that may be associated with the allergy.

Q: Does Ebastel D treat nasal congestion or just allergy symptoms?

Ebastel D is a combination product designed to address both general allergy symptoms and nasal congestion. The antihistamine component (Ebastine) targets the allergic symptoms, while the decongestant component (Pseudoephedrine) helps with nasal and sinus congestion.

Q: What drug class does Ebastel D belong to?

This fixed-dose medication contains two distinct components, classifying it as a combination of an Antihistamine (Ebastine) and a Nasal Decongestant (Pseudoephedrine).

Q: What is the difference between Ebastel D and the version without the 'D'?

The key difference lies in the composition of the tablet. The version designated with 'D' includes the decongestant Pseudoephedrine alongside the antihistamine Ebastine, whereas the non-'D' version contains only the antihistamine.

Q: Is Ebastel D considered a sedative or non-sedative medication?

While the antihistamine component is often described as non-sedating, official documents list sleepiness or drowsiness as a common side effect of the combination product. Official labeling indicates that awareness of this potential effect is required.

Q: How long does it typically take for Ebastel D to start working?

Studies on the components of the medication indicate that a positive clinical benefit, meaning a noticeable improvement in symptoms, is often observed starting from the first day of treatment.

Q: Can Ebastel D be used for chronic skin conditions like urticaria (hives)?

Official documents for the antihistamine component, Ebastine, often include the treatment of chronic idiopathic urticaria (hives) as an indication. However, its use for this condition is subject to determination by a health professional.

Q: Is Ebastel D used to treat symptoms of seasonal or perennial allergies?

Regulatory documents indicate that this medication is used to treat symptoms of both seasonal allergic rhinitis (such as hay fever) and perennial allergic rhinitis (year-round allergies).

Q: What are the most commonly reported side effects of Ebastel D?

According to the official product monograph, the most frequently reported side effects associated with the drug generally include headache, dry mouth, and feelings of drowsiness or sleepiness.

Q: Is drowsiness a frequent side effect of Ebastel D?

Yes, drowsiness or sleepiness is officially listed in regulatory documents as a frequent (common) side effect of this medication.

Q: Are there any serious or rare side effects associated with Ebastel D use?

Regulatory documents note that rare but serious side effects include severe allergic reactions, disturbances in heart rhythm (such as palpitations or tachycardia), and signs of liver dysfunction. Regulatory labeling requires patient awareness of these serious, though uncommon, effects.

Q: Does Ebastel D carry any risk of cardiovascular or heart-related side effects?

Official warnings indicate that the medication may carry a risk of certain cardiovascular effects. These can include an increase in heart rate (tachycardia), palpitations (feeling a fluttering heart), and hypertension (increased blood pressure).

Q: Is Ebastel D safe for people with high blood pressure?

Regulatory warnings state that the medication is generally contraindicated (should not be used) in patients who have severe high blood pressure or severe coronary heart disease. For individuals with less severe cardiovascular conditions, consultation with a health professional is advised in regulatory documents.

Q: What types of medications are known to interact with Ebastel D?

Official documents list that the drug can interact with several classes of medications. This includes Monoamine Oxidase Inhibitors (MAOIs), certain macrolide antibiotics (like erythromycin), and some antifungal medications (like ketoconazole).

Q: Does Ebastel D interact with commonly used over-the-counter cold and flu products?

Yes, official information advises that the decongestant component of this medication may interact with other over-the-counter products. Official information suggests caution when taking it alongside other medicines that contain sympathomimetic drugs or decongestants.

Q: Is it acceptable to consume alcohol while taking Ebastel D?

Official warnings advise that alcoholic drinks should be avoided while taking this medication. Alcohol may increase the risk of experiencing drowsiness or significantly reduce alertness.

Q: What is the safety classification of Ebastel D for use during pregnancy?

Regulatory guidance states that the use of this medication during pregnancy is only advised after a health professional has determined that the potential benefit justifies any potential risk.

Q: Is there any official guidance on using Ebastel D while breastfeeding?

Official documents advise that individuals should consult with a health professional regarding the use of this medication while breastfeeding. Consultation with a health professional is advised in regulatory documents.

Q: Does taking Ebastel D affect the ability to drive or operate machinery?

Because this medicine may cause sleepiness or reduced alertness, regulatory documents advise caution when performing activities that require full focus. This includes driving a car or operating heavy or dangerous machinery.

Q: How does the effectiveness of Ebastel D compare to Loratadine or Cetirizine in studies?

Studies that have examined the antihistamine component, Ebastine, often found that it improved symptoms of allergic rhinitis to a similar extent as other common antihistamines like loratadine and cetirizine.

Q: Is there research data to support the use of higher doses of Ebastel D for severe allergies?

Clinical trials have investigated the use of the antihistamine component, Ebastine, at higher doses for certain conditions. However, the fixed-dose combination product is restricted to its approved formulation, and the appropriate dosage must be determined by a health professional.

Q: Why is the 'D' component often included in allergy medicines like Ebastel D?

The 'D' component, which is Pseudoephedrine, is included because it acts as a nasal decongestant. Its purpose is to provide temporary relief from symptoms of nasal and sinus congestion and pressure.

Q: What should be done if an allergic reaction occurs after taking Ebastel D?

Official documents advise that if signs of a severe allergic reaction occur, such as cold sweat, difficulty breathing, or a severe rash, the medicine should be stopped immediately. Following this, emergency medical attention is required.

Q: Does Ebastel D interact with specific classes of antibiotics, such as macrolides?

Yes, official product information indicates that the medication is known to interact with certain classes of antibiotics. This includes macrolide antibiotics like erythromycin.

Q: Is there any known interaction between Ebastel D and antifungal medications?

Yes, regulatory documents note that the medication is known to interact with certain antifungal medications, such as ketoconazole.

Q: What is the significance of Ebastel D being a second-generation antihistamine?

The antihistamine component, Ebastine, is classified as a second-generation H1-receptor antagonist. Antihistamines in this class are typically associated with reduced central nervous system effects, such as less sedation, compared to the older first-generation drugs.

Q: Is it true that Ebastel D can cause a dry mouth?

Yes, dry mouth is listed in the official product monograph as a frequent (common) side effect of this medication.

Q: Can Ebastel D cause insomnia or difficulty sleeping in some users?

Yes, official product information lists sleeplessness (insomnia) and nervousness or excitability as possible side effects. These effects are often associated with the decongestant component of the medication.

Q: Does the 'D' component of Ebastel D have any potential for misuse or dependency?

The decongestant component, Pseudoephedrine, belongs to a class of drugs known as sympathomimetics. While not a primary warning for this combination product, official information about the component mentions the potential for excitability, and it carries regulatory restrictions.

Q: What is the usual duration of action for one dose of Ebastel D?

Regulatory information indicates that the drug is designed to provide effective relief throughout a 12-hour period. This is the basis for the maximum recommended interval between doses. The final determination of the appropriate dosing schedule is made by a health professional.

Q: What are the concerns about using Ebastel D if a person has liver or kidney impairment?

Official product information indicates that if a person has existing liver or kidney disease, consultation with a health professional is advised in regulatory documents. This is because these conditions may affect how the drug is processed by the body, as these conditions may require dose adjustments as outlined in the official documents.

Q: Is Ebastel D suitable for children, and what are the age restrictions?

According to regulatory documents, this medication is indicated for use in adults and adolescents who are 12 years of age and older. Use in children under 12 years is generally not recommended, and its use for this population is reserved for consultation with a health professional.

Q: What is the official guidance on taking Ebastel D for long periods?

Official guidance documents state that this medication is indicated for short-term use for symptomatic relief. Official guidance suggests that the duration of use should not exceed a period of seven days.

Q: Can Ebastel D be taken at night, or is it better to take it in the morning?

Regulatory guidelines for the product often suggest that it is best taken in the morning. Official guidance suggests taking it in the morning.

Q: What general expectations should patients have about symptom relief with Ebastel D?

The medication is officially indicated for the temporary relief of a range of allergic rhinitis symptoms. This relief may include reducing sneezing, runny nose, itchy/watery eyes, and nasal congestion.

Storage and Disposal of Ebastel D

The storage and handling of Ebastel D (Ebastine/Pseudoephedrine tablets) must strictly adhere to the conditions documented in official regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically 20°C to 25°C (68°F to 77°F).
Protection	The product must be protected from light and moisture.
Container	Keep the medicine in the original container and do not use if blister units are torn.
Child Safety	Must be kept out of the sight and reach of children.

Disposal Instructions

Official guidance requires that unused or expired tablets be disposed of properly. The preferred method is to use a drug take-back program. If no program is available, the tablets must be mixed with an undesirable substance (such as used coffee grounds) and sealed in a container before being placed in the household trash. The medicine should not be flushed down a toilet or sink.